Literature DB >> 31909584

Generation of a Novel Mouse Model of Parkinson's Disease via Targeted Knockdown of Glutamate Transporter GLT-1 in the Substantia Nigra.

Yunlong Zhang1,2, Xingjun Meng3, Zhigang Jiao3, Yan Liu4, Xiuping Zhang5, Shaogang Qu3.   

Abstract

Parkinson's disease (PD) is a common neurodegenerative disease that is characterized by pathological dopaminergic (DA) neuronal death and α-synuclein aggregation. Glutamate excitotoxicity is a well-established pathogenesis of PD that involves dysfunctional expression of glutamate transporters. Glutamate transporter-1 (GLT-1) is mainly responsible for clearance of glutamate at synapses, including DA synapses. However, the role of GLT-1 in the aberrant synaptic transmission in PD remains elusive. In the present study, we generated small-interfering RNAs (siRNAs) to knockdown GLT-1 expression in primary astrocytes, and we report that siRNA knockdown of astrocytic GLT-1 decreased postsynaptic density-95 (PSD-95) expression in neuron-astrocyte cocultures in vitro. Using adeno-associated viruses (AAVs) targeting GLT-1 short-hairpin RNA (shRNA) sequences with a glial fibrillary acidic protein (GFAP) promoter, we abolished astrocytic GLT-1 expression in the substantia nigra pars compacta (SNpc) of mice. We found that GLT-1 deficiency in the SNpc induced parkinsonian phenotypes in terms of progressive motor deficits and nigral DA neuronal death in mice. We also found that there were reactive astrocytes and microglia in the SNpc upon GLT-1 knockdown. Furthermore, we used RNA sequencing to determine altered gene expression patterns upon GLT-1 knockdown in the SNpc, which revealed that disrupted calcium signaling pathways may be responsible for GLT-1 deficiency-mediated DA neuronal death in the SNpc. Taken together, our findings provide evidence for a novel role of GLT-1 in parkinsonian phenotypes in mice, which may contribute to further elucidation of the mechanisms of PD pathogenesis.

Entities:  

Keywords:  Parkinson’s disease; RNA sequencing; calcium signaling; dopamine neuron; glutamate excitotoxicity; glutamate transporters

Mesh:

Substances:

Year:  2020        PMID: 31909584     DOI: 10.1021/acschemneuro.9b00609

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  12 in total

1.  Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake.

Authors:  Michael F Salvatore; Ella A Kasanga; D Parker Kelley; Katy E Venable; Tamara R McInnis; Mark A Cantu; Jennifer Terrebonne; Kathryn Lanza; Samantha M Meadows; Ashley Centner; Christopher Bishop; Donald K Ingram
Journal:  Geroscience       Date:  2022-05-30       Impact factor: 7.713

Review 2.  The role of excitatory amino acid transporter 2 (EAAT2) in epilepsy and other neurological disorders.

Authors:  Sahar Alijanpour; Mohammad Miryounesi; Soudeh Ghafouri-Fard
Journal:  Metab Brain Dis       Date:  2022-09-29       Impact factor: 3.655

3.  Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease.

Authors:  Ludovica Iovino; Veronica Giusti; Francesca Pischedda; Elena Giusto; Nicoletta Plotegher; Antonella Marte; Ilaria Battisti; Angela Di Iacovo; Algerta Marku; Giovanni Piccoli; Rina Bandopadhyay; Carla Perego; Tiziana Bonifacino; Giambattista Bonanno; Cristina Roseti; Elena Bossi; Giorgio Arrigoni; Luigi Bubacco; Elisa Greggio; Sabine Hilfiker; Laura Civiero
Journal:  Acta Neuropathol       Date:  2022-05-21       Impact factor: 15.887

Review 4.  Astrocytic Calcium and cAMP in Neurodegenerative Diseases.

Authors:  Marta Sobolczyk; Tomasz Boczek
Journal:  Front Cell Neurosci       Date:  2022-05-19       Impact factor: 6.147

Review 5.  Neuron-Astrocyte Interactions in Parkinson's Disease.

Authors:  Ikuko Miyazaki; Masato Asanuma
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

6.  Trojan Horse Delivery of 4,4'-Dimethoxychalcone for Parkinsonian Neuroprotection.

Authors:  Wenlong Zhang; Huaqing Chen; Liuyan Ding; Junwei Gong; Mengran Zhang; Wenyuan Guo; Pingyi Xu; Shiying Li; Yunlong Zhang
Journal:  Adv Sci (Weinh)       Date:  2021-03-03       Impact factor: 16.806

Review 7.  Emerging Roles for Aberrant Astrocytic Calcium Signals in Parkinson's Disease.

Authors:  Eric A Bancroft; Rahul Srinivasan
Journal:  Front Physiol       Date:  2022-01-11       Impact factor: 4.566

8.  Olfactory bulb astrocytes mediate sensory circuit processing through Sox9 in the mouse brain.

Authors:  Kevin Ung; Teng-Wei Huang; Brittney Lozzi; Junsung Woo; Elizabeth Hanson; Brandon Pekarek; Burak Tepe; Debosmita Sardar; Yi-Ting Cheng; Gary Liu; Benjamin Deneen; Benjamin R Arenkiel
Journal:  Nat Commun       Date:  2021-09-01       Impact factor: 14.919

Review 9.  Glutamic Acid Transporters: Targets for Neuroprotective Therapies in Parkinson's Disease.

Authors:  Xiang Li; Wenjun Wang; Jianghong Yan; Fancai Zeng
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

10.  Functional validation of a human GLUD2 variant in a murine model of Parkinson's disease.

Authors:  Wenlong Zhang; Junwei Gong; Liuyan Ding; Zhiling Zhang; Xiaowen Pan; Xiang Chen; Wenyuan Guo; Xiaokang Zhang; Xinling Yang; Guoyou Peng; Yuwan Lin; Feng Gao; Yuanquan Li; Xiaoqin Zhu; Aiguo Xuan; Shu Wang; Xiangdong Sun; Yunlong Zhang; Pingyi Xu
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.